Investigating the molecular chaperone DNAJA2 as an inhibitor of tau aggregate pathology in Alzheimer’s Alzheimer’s Disease is a progressive and fatal disease that currently afflicts up to 400,000 Canadians over the age of 65. Grant type Capacity building grants Area of Research Neurodegeneration Competition Future Leaders in Canadian Brain Research Province Alberta Start Date 2021
